NCT01959373

Brief Summary

Amyotrophic lateral sclerosis (ALS) is characterized clinically by abnormalities of both upper motor neurons (UMN) and lower motor neurons (LMN). The presence of UMN signs is not always easy to establish. The only technique used in routine to assess the corticospinal dysfunctions is based on transcranial magnetic stimulation (TMS). However, this technique is largely dependent on LMN state and is based on artificial motor cortex activation. The main objective of our study project is to evaluate a new method assessing functional changes in motor system in ALS patients. By using cortico-muscular and cortico-cortical coherences, it could be possible to show modifications in both cortico-muscular relationship and in cortical activity coordination which could be related to clinical state in ALS patients. We notably expect a decrease in cortico-muscular coherence in ALS patients. Furthermore, these analyses could provide new insights in motor system plasticity phenomena. We expect a partial covering of voluntary motor command by cortical areas adjacent to primary motor cortex. Lastly, the hypothesis that an increased proportion of voluntary motor control may be assumed by ipsilateral corticospinal tract could be tested by coherence analyses. Coherence analysis might be a useful method to detect corticospinal tract dysfunctions. This method has the advantage to be painless and not to use artificial stimulations as it is used in TMS.

Trial Health

40
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial recruitment is currently suspended
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
suspended

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2013

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

October 8, 2013

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 10, 2013

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2014

Completed
Last Updated

August 24, 2015

Status Verified

August 1, 2015

Enrollment Period

9 months

First QC Date

October 8, 2013

Last Update Submit

August 21, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • recording neuronal activities

    simultaneous recording of brain activity using electrodes attached to the scalp and muscle activities of muscles of the hands with electrodes bonded to the skin.

    12 months

Secondary Outcomes (1)

  • identify plasticity phenomena

    12 months

Study Arms (2)

patients

EXPERIMENTAL
Procedure: electroencephalograms (EEG)Procedure: electro-myography (EMG)

healthy volunteers

EXPERIMENTAL
Procedure: electroencephalograms (EEG)Procedure: electro-myography (EMG)

Interventions

healthy volunteerspatients
healthy volunteerspatients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient female or male, more than 18 years,
  • Patien with a diagnosis of amyotrophic lateral sclerosis according to the El Escorial criteria of Brooks et al. 1994
  • Patient , the beginning of the SLA date less than 12 months,
  • Patient not having a familial form of ALS,
  • Patient not having cancer, autoimmune disease, liver failure, severe hypertension or untreated, severe conduction disorders or uncontrolled arrhythmia
  • Patient not having a chronic psychiatric disease, dementia.
  • Patient with normal visual function
  • Patients receiving social coverage
  • Patient have read, understood and signed an informed consent after information

You may not qualify if:

  • Patient minor
  • Patient with a familial form of ALS,
  • Patient associated with severe progressive disease (cancer, autoimmune disease , liver failure )
  • Patient (s) with chronic mental illness, dementia ,
  • Presence of atypical clinical signs such as cerebellar ataxia , extrapyramidal signs, sensory disorders , autonomic dysfunction .
  • Clinical signs of chronic respiratory failure or slow and / or forced less than 70% of the theoretical value or chronic hypercapnia than 45 mmHg vital capacity .
  • Patient private freedom following a judicial or administrative decision
  • Patient major Trust
  • Pateinte pregnant, parturient , lactating
  • Patient major in legal protection ( guardianship )
  • Pateinte pregnant , parturient , lactating
  • Patient hospital without consent
  • Patient admitted in a health or social establishment for purposes other than research

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assistance Publique Hopitaux de Marseille

Marseille, 13354, France

Location

MeSH Terms

Conditions

Amyotrophic Lateral Sclerosis

Condition Hierarchy (Ancestors)

Spinal Cord DiseasesCentral Nervous System DiseasesNervous System DiseasesMotor Neuron DiseaseNeurodegenerative DiseasesTDP-43 ProteinopathiesNeuromuscular DiseasesProteostasis DeficienciesMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • LOIC MONDOLONI

    Assistance Publique Hopitaux De Marseille

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 8, 2013

First Posted

October 10, 2013

Study Start

October 1, 2013

Primary Completion

July 1, 2014

Last Updated

August 24, 2015

Record last verified: 2015-08

Locations